Processa pharmaceuticals provides portfolio and business update

Signed binding term sheet granting intact therapeutics an exclusive option to license pcs12852 continue enrolling patients in phase 2 study of pcs6422 strengthened balance sheet with $7m capital infusion vero beach, fla., july 01, 2025 (globe newswire) -- processa pharmaceuticals, inc. (nasdaq: pcsa), a clinical-stage pharmaceutical company developing next-generation cancer therapies, provides updates on its product pipeline, upcoming milestones and business activities.
PCSA Ratings Summary
PCSA Quant Ranking